AC
BMRN icon

Alexandria Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alexandria Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-26
Closed -$2K – 268
2017
Q3 		$2K Sell
26
-43
-62% -$3.8K ﹤0.01% 500
2017
Q2 		$6K Sell
69
-14
-17% -$1.27K ﹤0.01% 463
2017
Q1 		$7K Sell
83
-4
-5% -$356 ﹤0.01% 449
2016
Q4 		$7K Buy
87
+9
+12% +$774 ﹤0.01% 446
2016
Q3 		$7K Buy
78
+23
+42% +$2.17K ﹤0.01% 450
2016
Q2 		$4K Buy
55
+18
+49% +$1.53K ﹤0.01% 495
2016
Q1 		$3K Buy
37
+10
+37% +$814 ﹤0.01% 528
2015
Q4 		$3K Buy
27
+13
+93% +$1.36K ﹤0.01% 573
2015
Q3 		$1K Buy
+14
New +$1.87K ﹤0.01% 563

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Alexandria Capital's BMRN Position: Q4 2017 in Review

Alexandria Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 26 shares — an estimated $2K sold.

Alexandria Capital first reported a position in BMRN in Q3 2015 and held it in 9 quarters. The position peaked at $7K in Q1 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

  • Alexandria Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Alexandria Capital sold 26 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $2K.
  • Alexandria Capital first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 9 quarters.
  • Alexandria Capital's BioMarin Pharmaceuticals position peaked at $7K in Q1 2017.
  • 438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Alexandria Capital's 13F filing for Q4 2017, filed 9 Feb 2018.